How This Evidence Evolved
Penicillin Allergy Delabeling
From Lifetime Avoidance to Safe Rechallenge
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Safety of direct oral amoxicillin challenge
Oral challenge safety in low-risk cancer patients
Allergy: 4/155 (2.6%, 95% CI 1.0–6.5%), all mild challenge reactions, vs 14/170 (8.2%) historical patients: 11 positive skin tests and 3 challenge reactions
Positive skin test at 5 years: group A 12 of 31 vs group B 0 of 24 (log-rank 12.8)
Hospital use and infections, penicillin 'allergy' vs matched controls: 0.59 more hospital days (95% CI 0.47-0.71); 23.4% more C difficile, 14.1% more MRSA, 30.1% more VRE
MRSA and C difficile over mean 6.0 years: penicillin allergy vs comparators (adjusted HR 1.69, 95% CI 1.51-1.90 for MRSA; 1.26, 1.12-1.40 for C difficile)
Follow-up studies, subgroup analyses, and real-world validation
Pediatric electronic allergy-risk classification compared with allergist assessment
Positive immune-mediated oral challenge within 1 hour: direct challenge 1 of 187 (0.5%) vs skin test then challenge 1 of 190 (0.5%) (RD 0.0084 pp, 90% CI -1.22 to 1.24; noninferiority margin 5 pp)
Current standard of care and ongoing research directions
Landmark Trials in This Story
Clinical practice guidelines for antimicrobial prophylaxis in surgery
Guideline on surgical antimicrobial prophylaxis
Patients with positive skin test results to penicillin should not undergo penicillin or amoxicillin challenge
Letter on challenges after positive penicillin skin tests
Comparing Direct Challenge to Penicillin Skin Testing for the Outpatient Evaluation of Penicillin Allergy: A Randomized Controlled Trial
Safety of direct oral amoxicillin challenge
The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study
Oral challenge safety in low-risk cancer patients
Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing.
Allergy: 4/155 (2.6%, 95% CI 1.0–6.5%), all mild challenge reactions, vs 14/170 (8.2%) historical patients: 11 positive skin tests and 3 challenge reactions
Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics.
Positive skin test at 5 years: group A 12 of 31 vs group B 0 of 24 (log-rank 12.8)
Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study.
Hospital use and infections, penicillin 'allergy' vs matched controls: 0.59 more hospital days (95% CI 0.47-0.71); 23.4% more C difficile, 14.1% more MRSA, 30.1% more VRE
Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study.
MRSA and C difficile over mean 6.0 years: penicillin allergy vs comparators (adjusted HR 1.69, 95% CI 1.51-1.90 for MRSA; 1.26, 1.12-1.40 for C difficile)
First pediatric electronic algorithm to stratify risk of penicillin allergy
Pediatric electronic allergy-risk classification compared with allergist assessment
Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial.
Positive immune-mediated oral challenge within 1 hour: direct challenge 1 of 187 (0.5%) vs skin test then challenge 1 of 190 (0.5%) (RD 0.0084 pp, 90% CI -1.22 to 1.24; noninferiority margin 5 pp)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.